Shandong Wohua Pharmaceutical Co (SZSE:002107) Risk Assessment

View and export this data going back to 2007. Start your Free Trial

What is Shandong Wohua Pharmaceutical Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Shandong Wohua Pharmaceutical Co is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of Shandong Wohua Pharmaceutical Co's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Shandong Wohua Pharmaceutical Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shandong Wohua Pharmaceutical Co's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shandong Wohua Pharmaceutical Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Shandong Wohua Pharmaceutical Co's Risk Assessment falls into.

Shandong Wohua Pharmaceutical Co (SZSE:002107) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Shandong Wohua Pharmaceutical Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Shandong Wohua Pharmaceutical Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Shandong Wohua Pharmaceutical Co (SZSE:002107) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Wohua Pharmaceutical Co Ltd (SZSE:002107) » Definitions » Risk Assessment

Traded in Other Exchanges

N/A

Address

Fushou East Street, Chuangye Building, 2F, New and High-Tech Industrial Development Zone, Huaifang, Shandong, CHN, 261011

Website

http://www.wohua.cn

Shandong Wohua Pharmaceutical Co Ltd is a China-based company specializing in the field of cardio-cerebral vascular medicine. The company's main products consist of Xinkeshu tablets for the treatment of coronary heart disease; Naoxueshu oral liquid, promoting blood circulation by removing blood stasis; Hupo Xiaoshi granules for the treatment of urethral calculus, and Yuandu granules for the treatment of influenza, among others.

Executives

Zhao Jun	Director
Liu Wen Yi	Supervisors
Zhang Fa Zhong	Supervisors
Zhang Ge	Director
Ma Xing Chen	Supervisors
Tian Kai Ji	Directors, executives
Kong Xian Jun	Supervisors

Shandong Wohua Pharmaceutical Co (SZSE:002107) Headlines

No Headlines